688276 百克生物
已收盘 11-06 15:00:00
资讯
新帖
简况
百克生物：2026年1-9月份，公司营业收入同比增长18.84%
证券之星 · 11-06 17:04
百克生物：2026年1-9月份，公司营业收入同比增长18.84%
百克生物：前三季度经营活动现金流量净额较上年同期显著改善
证券之星 · 11-06 17:03
百克生物：前三季度经营活动现金流量净额较上年同期显著改善
【机构调研记录】明亚基金调研百克生物、澳华内镜
证券之星 · 11-02
【机构调研记录】明亚基金调研百克生物、澳华内镜
百克生物（688276）披露2026年第三季度报告，10月30日股价下跌2.28%
证券之星 · 10-30
百克生物（688276）披露2026年第三季度报告，10月30日股价下跌2.28%
百克生物(688276)9月30日股东户数1.38万户，较上期增加19.2%
证券之星 · 10-30
百克生物(688276)9月30日股东户数1.38万户，较上期增加19.2%
百克生物：接种时间可由约2分钟减少为8秒
证券之星 · 10-30
百克生物：接种时间可由约2分钟减少为8秒
百克生物：带状疱疹疫苗终端接种逐渐回暖
证券之星 · 10-30
百克生物：带状疱疹疫苗终端接种逐渐回暖
百克生物：有序推进研发、生产、批签及销售工作
证券之星 · 10-30
百克生物：有序推进研发、生产、批签及销售工作
百克生物：深化既有市场，突破重点项目，拓展经销商网络，提升国际化影响力
证券之星 · 10-30
百克生物：深化既有市场，突破重点项目，拓展经销商网络，提升国际化影响力
百克生物：在研项目冻干狂犬疫苗（人二倍体细胞）正在开展III期临床试验
证券之星 · 10-30
百克生物：在研项目冻干狂犬疫苗（人二倍体细胞）正在开展III期临床试验
百克生物：参股公司传信生物布局通用型及个性化肿瘤mRNA疫苗
证券之星 · 10-30
百克生物：参股公司传信生物布局通用型及个性化肿瘤mRNA疫苗
图解百克生物三季报：第三季度单季净利润同比增长48.60%
证券之星 · 10-30
图解百克生物三季报：第三季度单季净利润同比增长48.60%
股市必读：百克生物（688276）10月23日董秘有最新回复
证券之星 · 10-26
股市必读：百克生物（688276）10月23日董秘有最新回复
百克生物：有序推进研发、生产、批签及销售工作
证券之星 · 10-23
百克生物：有序推进研发、生产、批签及销售工作
股市必读：百克生物新发布《长春百克生物科技股份公司关于召开2026年第三季度业绩说明会的公告》
证券之星 · 10-23
股市必读：百克生物新发布《长春百克生物科技股份公司关于召开2026年第三季度业绩说明会的公告》
百克生物（688276）披露召开2026年第三季度业绩说明会公告，10月21日股价下跌0.42%
证券之星 · 10-21
百克生物（688276）披露召开2026年第三季度业绩说明会公告，10月21日股价下跌0.42%
股市必读：百克生物（688276）10月16日董秘有最新回复
证券之星 · 10-19
股市必读：百克生物（688276）10月16日董秘有最新回复
百克生物：HSV-2 mRNA疫苗正在开展I期临床试验
证券之星 · 10-16
百克生物：HSV-2 mRNA疫苗正在开展I期临床试验
百克生物（688276）10月15日主力资金净卖出298.46万元
证券之星 · 10-16
百克生物（688276）10月15日主力资金净卖出298.46万元
股市必读：百克生物（688276）10月9日董秘有最新回复
证券之星 · 10-12
股市必读：百克生物（688276）10月9日董秘有最新回复
加载更多
公司概况
公司名称：
长春百克生物科技股份公司
所属行业：
医药制造业
上市日期：
2021-06-25
主营业务：
长春百克生物科技股份公司的主营业务是传染病防治的创新生物药的研发、生产及销售。公司的主要产品是水痘疫苗、鼻喷流感疫苗、带状疱疹疫苗、液体鼻喷流感疫苗。
发行价格：
36.35
{"stockData":{"symbol":"688276","market":"SH","secType":"STK","nameCN":"百克生物","latestPrice":16.18,"timestamp":1793948400000,"preClose":16.53,"halted":0,"volume":2278229,"delay":0,"changeRate":-0.0212,"floatShares":413999999,"shares":413999999,"eps":-0.4834,"marketStatus":"已收盘","change":-0.35,"latestTime":"11-06 15:00:00","open":16.2,"high":16.47,"low":15.99,"amount":36950300,"amplitude":0.029,"askPrice":16.18,"askSize":1,"bidPrice":16.17,"bidSize":97,"shortable":0,"etf":0,"ttmEps":-0.4834,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":5,"adr":0,"adjPreClose":16.53,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":18.18,"lowLimit":14.88,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":413657598,"isCdr":false,"pbRate":1.79,"roa":"--","roe":"--","epsLYR":-0.64,"committee":0.690821,"marketValue":6693000000,"turnoverRate":0.0055,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-09。","afterMarket":{"amount":0,"volume":0,"close":16.18,"buyVolume":0,"sellVolume":0,"time":1793950437746,"indexStatus":"已收盘 11-06 15:30:00","preClose":16.53},"floatMarketCap":6693000000},"requestUrl":"/m/hq/s/688276","defaultTab":"news","newsList":[{"id":"2681937859","title":"百克生物：2026年1-9月份，公司营业收入同比增长18.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681937859","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681937859?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:04","pubTimestamp":1793955886,"startTime":"0","endTime":"0","summary":"证券之星消息，百克生物11月06日在投资者关系平台上答复投资者关心的问题。请问：1. 从三季报数据看，该产品终端批签发与销售量同比增速是多少？降价策略是否已使收入贡献重新转正？百克生物回复：尊敬的投资者您好，2026年1-9月份，公司营业收入同比增长18.84%、利润亏损幅度大幅收窄，主要系公司流感疫苗及带状疱疹疫苗销量增加，带动了盈利水平改善。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600028547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681085918","title":"百克生物：前三季度经营活动现金流量净额较上年同期显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2681085918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681085918?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:03","pubTimestamp":1793955820,"startTime":"0","endTime":"0","summary":"证券之星消息，百克生物11月06日在投资者关系平台上答复投资者关心的问题。请问：1. 现金流变化主要源于应收账款回款周期延长还是销售季节性波动？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600028541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680678538","title":"【机构调研记录】明亚基金调研百克生物、澳华内镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2680678538","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680678538?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:04","pubTimestamp":1793577883,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月30日披露的机构调研信息，明亚基金近期对2家上市公司进行了调研，相关名单如下：1）百克生物 调研纪要：前三季度，公司实现营业收入56,383.72万元，同比增长18.84%；实现归属于上市公司股东的净利润-9,562.55万元，同比减亏6,262.50万元。流感疫苗及带状疱疹疫苗销量增加带动盈利改善。明亚基金成立于2019年，截至目前，资产管理规模15.62亿元；资产管理规模15.62亿元；管理公募基金数18只；旗下公募基金经理5人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200002278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688212","688276","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679221675","title":"百克生物（688276）披露2026年第三季度报告，10月30日股价下跌2.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679221675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679221675?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:53","pubTimestamp":1793361211,"startTime":"0","endTime":"0","summary":"截至2026年10月30日收盘，百克生物报收于15.43元，较前一交易日下跌2.28%，最新总市值为63.83亿元。百克生物于近日披露《2026年第三季度报告》。报告显示，本报告期营业收入为259,321,551.49元，同比增长36.81%；年初至报告期末营业收入为563,837,192.71元，同比增长18.84%。本报告期研发投入合计为38,208,080.40元，同比下降52.06%；年初至报告期末研发投入合计为140,920,093.32元，同比下降20.79%。本报告期归属于上市公司股东的净利润为-43,525,342.31元；年初至报告期末为-95,625,458.79元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000050036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679213833","title":"百克生物(688276)9月30日股东户数1.38万户，较上期增加19.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679213833","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679213833?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:11","pubTimestamp":1793358718,"startTime":"0","endTime":"0","summary":"证券之星消息，近日百克生物披露，截至2026年9月30日公司股东户数为1.38万户，较6月30日增加2227.0户，增幅为19.2%。在生物制品行业个股中，百克生物股东户数低于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.67万户。根据统计，百克生物2026年6月30日至2026年9月30日，主力资金净流出3963.65万元，游资资金净流出3174.49万元，散户资金净流入7138.14万元。期间龙虎榜该股共上榜1次。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000046574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679968192","title":"百克生物：接种时间可由约2分钟减少为8秒","url":"https://stock-news.laohu8.com/highlight/detail?id=2679968192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679968192?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:09","pubTimestamp":1793351374,"startTime":"0","endTime":"0","summary":"证券之星消息，百克生物10月30日在投资者关系平台上答复投资者关心的问题。公司鼻喷流感疫苗液体剂型为在公司原有冻干鼻喷流感疫苗的基础上进行的剂型升级，接种时间可有原来约2分钟减少为8秒，极大的提升了接种便利度。公司重点围绕液体剂型的优势和特点，着力提升接种点覆盖率，提升家长对流感预防的重视程度，助力提高流感疫苗接种渗透率，为守护儿童健康贡献力量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000041919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679296820","title":"百克生物：带状疱疹疫苗终端接种逐渐回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2679296820","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679296820?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:09","pubTimestamp":1793351353,"startTime":"0","endTime":"0","summary":"百克生物回复：尊敬的投资者您好，2026年前三季度，公司在营销层面系统实施了从产品价格重塑到营销体系优化的组合策略：在产品价格层面，通过对带状疱疹疫苗产品的主动价格管理，提升产品可及性，扩大适龄人群覆盖率；在渠道深耕方面，优化渠道考核与库存管控，依托主动的价格调整，推动带状疱疹疫苗终端接种逐渐回暖。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000041903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679003293","title":"百克生物：有序推进研发、生产、批签及销售工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2679003293","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679003293?lang=zh_cn&edition=full","pubTime":"2026-10-30 16:54","pubTimestamp":1793350463,"startTime":"0","endTime":"0","summary":"证券之星消息，百克生物10月30日在投资者关系平台上答复投资者关心的问题。公司如有相关计划，将及时履行信息披露义务，感谢您的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000041382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679629370","title":"百克生物：深化既有市场，突破重点项目，拓展经销商网络，提升国际化影响力","url":"https://stock-news.laohu8.com/highlight/detail?id=2679629370","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679629370?lang=zh_cn&edition=full","pubTime":"2026-10-30 16:54","pubTimestamp":1793350462,"startTime":"0","endTime":"0","summary":"请问：1. 除印度、印尼等既有市场外，公司下一阶段重点突破的目标市场有哪些？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000041379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679429582","title":"百克生物：在研项目冻干狂犬疫苗（人二倍体细胞）正在开展III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2679429582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679429582?lang=zh_cn&edition=full","pubTime":"2026-10-30 16:54","pubTimestamp":1793350451,"startTime":"0","endTime":"0","summary":"证券之星消息，百克生物10月30日在投资者关系平台上答复投资者关心的问题。公司冻干人用狂犬疫苗 已出口多国。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000041371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679029329","title":"百克生物：参股公司传信生物布局通用型及个性化肿瘤mRNA疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2679029329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679029329?lang=zh_cn&edition=full","pubTime":"2026-10-30 16:54","pubTimestamp":1793350451,"startTime":"0","endTime":"0","summary":"参股公司传信生物在肿瘤治疗性疫苗领域布局了通用型肿瘤mRNA疫苗和个性化肿瘤治疗疫苗两大研发方向，截至目前，传信生物通用型肿瘤mRNA疫苗项目正在进行IIT临床试验，目前该项目患者均已进入随访期；个性化治疗疫苗，目前处于临床前的早期研究阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000041370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679234869","title":"图解百克生物三季报：第三季度单季净利润同比增长48.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679234869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679234869?lang=zh_cn&edition=full","pubTime":"2026-10-30 04:53","pubTimestamp":1793307211,"startTime":"0","endTime":"0","summary":"证券之星消息，百克生物2026年三季报显示，前三季度公司主营收入5.64亿元，同比上升18.84%；归母净利润-9562.55万元，同比上升39.57%；扣非净利润-9696.28万元，同比上升46.05%；其中2026年第三季度，公司单季度主营收入2.59亿元，同比上升36.81%；单季度归母净利润-4352.53万元，同比上升48.6%；单季度扣非净利润-4344.69万元，同比上升55.44%；负债率27.2%，投资收益-3168.9万元，财务费用459.24万元，毛利率78.7%。财报数据概要请见下图:本文数据来源于百克生物2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000006305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678134604","title":"股市必读：百克生物（688276）10月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2678134604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678134604?lang=zh_cn&edition=full","pubTime":"2026-10-26 07:28","pubTimestamp":1792970890,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘，百克生物报收于16.01元，上涨2.04%，换手率0.95%，成交量3.91万手，成交额6051.31万元。目前，根据国家药品监督管理局官网信息，国内共获批上市4款RSV抗体，其中进口和国产产品各2款，上述4款RSV抗体均为单价产品。公司本次获得受理的RSV抗体为鸡尾酒组合制剂，相比单价抗体制剂，该产品具有更强的中和活性。当日关注点交易信息汇总：10月23日主力资金净流出81.99万元，占总成交额1.35%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600001871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677942570","title":"百克生物：有序推进研发、生产、批签及销售工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2677942570","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677942570?lang=zh_cn&edition=full","pubTime":"2026-10-23 16:57","pubTimestamp":1792745837,"startTime":"0","endTime":"0","summary":"证券之星消息，百克生物(688276)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问：公司市值是否会超越长春高新百克生物回复：尊敬的投资者您好，公司高度重视经营与发展，坚定看好公司长期发展，有序推进研发、生产、批签及销售工作。面对不断变化的外部环境，人口老龄化以及不断涌现的新技术、新产品带来的机遇与挑战，公司始终坚持高质量发展，不断完善在成人疫苗、多联多价疫苗以及mRNA疫苗等产品的管线布局，巩固和发展公司核心竞争力，以提高公司质量为基础，努力提升公司投资价值和股东回报能力，感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300030916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677993947","title":"股市必读：百克生物新发布《长春百克生物科技股份公司关于召开2026年第三季度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677993947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677993947?lang=zh_cn&edition=full","pubTime":"2026-10-23 02:43","pubTimestamp":1792694587,"startTime":"0","endTime":"0","summary":"截至2026年10月22日收盘，百克生物报收于15.69元，下跌4.5%，换手率0.68%，成交量2.82万手，成交额4506.93万元。当日关注点交易信息汇总：10月22日主力资金净流出662.99万元，占总成交额14.71%。公司公告汇总：百克生物将于10月30日15:00-16:00召开2026年第三季度业绩说明会，通过上证路演中心网络互动方式进行。投资者可于2026年10月23日至10月29日16:00前通过上证路演中心网站或公司邮箱ir@bchtpharm.com提问。说明会后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300002441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677670098","title":"百克生物（688276）披露召开2026年第三季度业绩说明会公告，10月21日股价下跌0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677670098","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677670098?lang=zh_cn&edition=full","pubTime":"2026-10-21 22:43","pubTimestamp":1792593793,"startTime":"0","endTime":"0","summary":"截至2026年10月21日收盘，百克生物报收于16.43元，较前一交易日下跌0.42%，最新总市值为67.96亿元。该股当日开盘16.67元，最高16.8元，最低16.32元，成交额达3178.77万元，换手率为0.46%。公告显示，公司将于2026年10月30日15:00-16:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会，介绍公司经营成果及财务状况。投资者可于2026年10月23日至10月29日16:00前通过上证路演中心网站或公司邮箱ir@bchtpharm.com提问。说明会后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100041717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676739855","title":"股市必读：百克生物（688276）10月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2676739855","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676739855?lang=zh_cn&edition=full","pubTime":"2026-10-19 03:15","pubTimestamp":1792350911,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘，百克生物报收于16.5元，下跌1.26%，换手率1.0%，成交量4.14万手，成交额7019.49万元。公司的HSV-2 mRNA疫苗后续临床试验的开展具有一定的不确定性，能否最终实现商业目的也存在一定的不确定性，敬请广大投资者谨慎决策，注意防范投资风险。当日关注点交易信息汇总：10月16日主力资金净流入252.1万元，占总成交额3.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900000989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675647775","title":"百克生物：HSV-2 mRNA疫苗正在开展I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2675647775","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675647775?lang=zh_cn&edition=full","pubTime":"2026-10-16 16:06","pubTimestamp":1792137972,"startTime":"0","endTime":"0","summary":"证券之星消息，百克生物10月16日在投资者关系平台上答复投资者关心的问题。公司的HSV-2 mRNA疫苗后续临床试验的开展具有一定的不确定性，能否最终实现商业目的也存在一定的不确定性，敬请广大投资者谨慎决策，注意防范投资风险。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600025806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675559187","title":"百克生物（688276）10月15日主力资金净卖出298.46万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675559187","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675559187?lang=zh_cn&edition=full","pubTime":"2026-10-16 08:21","pubTimestamp":1792110084,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月15日收盘，百克生物报收于16.71元，下跌0.42%，换手率0.77%，成交量3.18万手，成交额5348.39万元。10月15日的资金流向数据方面，主力资金净流出298.46万元，占总成交额5.58%，游资资金净流入658.81万元，占总成交额12.32%，散户资金净流出360.35万元，占总成交额6.74%。融券方面，融券卖出7600.0股，融券偿还0.0股，融券余量2.5万股，融券余额41.82万元。百克生物主营业务：人用疫苗等生物制品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600007253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674496628","title":"股市必读：百克生物（688276）10月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2674496628","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674496628?lang=zh_cn&edition=full","pubTime":"2026-10-12 05:02","pubTimestamp":1791752538,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，百克生物报收于17.79元，上涨2.65%，换手率0.95%，成交量3.93万手，成交额6806.12万元。其中，HSV-2 mRNA疫苗是公司mRNA技术平台的重磅产品，当前全球暂无相关疫苗产品成功开发上市。此外，公司投资的传信生物致力于mRNA技术的开发及应用，传信生物研发的通用型肿瘤mRNA疫苗正在开展IIT临床试验，截至2026年6月，已完成13例患者入组和全部计划给药，未出现DLT事件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200001630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793998407228,"stockEarnings":[{"period":"1week","weight":0.0486},{"period":"1month","weight":-0.0986},{"period":"3month","weight":0.0365},{"period":"6month","weight":-0.1254},{"period":"1year","weight":-0.2595},{"period":"ytd","weight":-0.1421}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":-0.0502},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.127},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":-0.0805}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春百克生物科技股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13826人(较上一季度增加19.20%)","perCapita":"29918股","listingDate":"2021-06-25","address":"吉林省长春市朝阳区高新开发区火炬路1260号","registeredCapital":"41365万元","survey":" 长春百克生物科技股份公司的主营业务是传染病防治的创新生物药的研发、生产及销售。公司的主要产品是水痘疫苗、鼻喷流感疫苗、带状疱疹疫苗、液体鼻喷流感疫苗。","listedPrice":36.35},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百克生物(688276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百克生物(688276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百克生物,688276,百克生物股票,百克生物股票老虎,百克生物股票老虎国际,百克生物行情,百克生物股票行情,百克生物股价,百克生物股市,百克生物股票价格,百克生物股票交易,百克生物股票购买,百克生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百克生物(688276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百克生物(688276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}